Sipuleucel-T in Metastatic Castration-Resistant Prostate CancerProfile Report

被引：0
|
作者：
Greg L. Plosker
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
BioDrugs | 2011年 / 25卷
关键词：
Prostate Cancer; Prostatic Acid Phosphatase; Metastatic CRPC; Therapeutic Cancer Vaccine; Leukapheresis Product;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：255 / 256
页数：1
相关论文
共 50 条
  • [1] Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
    Peter F. Mulders
    Maria De Santis
    Thomas Powles
    Karim Fizazi
    Cancer Immunology, Immunotherapy, 2015, 64 : 655 - 663
  • [2] SIPULEUCEL-T (PROVENGE®) FOR CASTRATION-RESISTANT PROSTATE CANCER
    Sartor, Oliver
    BJU INTERNATIONAL, 2012, 110 (2B) : E105 - E105
  • [3] Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
    Mulders, Peter F.
    De Santis, Maria
    Powles, Thomas
    Fizazi, Karim
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (06) : 655 - 663
  • [4] Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer
    Holko, Przemyslaw
    Kawalec, Pawel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (01) : 63 - 73
  • [5] Sipuleucel-TIn Metastatic Castration-Resistant Prostate Cancer
    Greg L. Plosker
    Drugs, 2011, 71 : 101 - 108
  • [6] The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature
    Sonpavde, Guru
    Di Lorenzo, Giuseppe
    Higano, Celestia S.
    Kantoff, Philip W.
    Madan, Ravi
    Shore, Neal D.
    EUROPEAN UROLOGY, 2012, 61 (04) : 639 - 647
  • [7] Immunotherapy for the treatment of castration resistant prostate cancer: sipuleucel-T
    Aslan, Guven
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2012, 11 (02): : 156 - 158
  • [8] Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer
    Higano, Celestia S.
    Armstrong, Andrew J.
    Sartor, A. Oliver
    Vogelzang, Nicholas J.
    Kantoff, Philip W.
    McLeod, David G.
    Pieczonka, Christopher M.
    Penson, David F.
    Shore, Neal D.
    Vacirca, Jeffrey
    Concepcion, Raoul S.
    Tutrone, Ronald F.
    Nordquist, Luke T.
    Quinn, David I.
    Kassabian, Vahan
    Scholz, Mark C.
    Harmon, Matt
    Tyler, Robert C.
    Chang, Nancy N.
    Tang, Hong
    Cooperberg, Matthew R.
    CANCER, 2019, 125 (23) : 4172 - 4180
  • [9] Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy
    Bilen, Mehmet Asim
    Hess, Kenneth R.
    Subudhi, Sumit K.
    Aparicio, Ana
    Kim, Jeri
    Zurita-Saavedra, Amado J.
    Araujo, John C.
    Corn, Paul G.
    Stover, Jessica
    Lin, Sue-Hwa
    Logothetis, Christopher J.
    Tu, Shi-Ming
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (03) : 583 - 589
  • [10] Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy
    Mehmet Asim Bilen
    Kenneth R. Hess
    Sumit K. Subudhi
    Ana Aparicio
    Jeri Kim
    Amado J. Zurita-Saavedra
    John C. Araujo
    Paul G. Corn
    Jessica Stover
    Sue-Hwa Lin
    Christopher J. Logothetis
    Shi-Ming Tu
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 583 - 589
12345